Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital, Strasbourg, France Association d'Aide aux Insuffisants Respiratoires d'Alsace Lorraine |
---|---|
Information provided by: | University Hospital, Strasbourg, France |
ClinicalTrials.gov Identifier: | NCT00476281 |
Diabetes is a important complication of cystic fibrosis (CF). The improved life expectancy of patients with cystic fibrosis, as a result of advances in medical therapy, has resulted in an increasing prevalence of cystic fibrosis-related diabetes (CFRD). CFRD is associated with accelerated pulmonary decline and increased mortality. Pulmonary effects are seen some years before the diagnosis of CFRD implying that impaired glucose tolerance may be very early detrimental. Insulin treatment is clearly indicated in patients with CFRD to control symptoms and reduce complications. However, at the state of impaired glucose tolerance or fasting hyperglycaemia, current screening methods are not suitable for the early management of hyperglycaemia.The recent introduction of the continuous glucose monitoring system (CGMS), which provides a continuous glucose profile, has revealed to be clinically relevant in the investigation of glucose excursions over a long period. This device, widely use in diabetic non cystic fibrosis patients, has been validated in non diabetic cystic fibrosis subjects. Previous studies of continuous glucose monitoring have been realized in CF patients with normal glucose tolerance and diabetes and compared with non CF controlThe aim of our study is to evaluate the glucose profile with continuous glucose monitoring the nutritional and respiratory status in cystic fibrosis subjects, according to their glucose tolerance.
Condition | Intervention |
---|---|
Cystic Fibrosis Diabetes |
Procedure: Urinary collect Procedure: Continuous Glucose Monitoring System (CGMS) |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | Evaluation of Nutritional, Metabolic and Respiratory Status in Young Adult Patients With Cystic Fibrosis |
Ages Eligible for Study: | 12 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Laurence KESSLER, MD | 33 3 88 11 65 95 | laurence.kessler@chru-strasbourg.fr |
France | |
Service d'Endocrinologie, Diabète et Maladies Métaboliques - Hôpital Civil | Recruiting |
Strasbourg, France, 67091 | |
Contact: Laurence KESSLER, MD 33 3 88 11 65 95 laurence.kessler@chru-strasbourg.fr | |
Principal Investigator: Laurence KESSLER, MD | |
Sub-Investigator: François MOREAU, MD | |
Service de Réanimation Médicale - Hôpital Civil | Recruiting |
Strasbourg, France, 67091 | |
Contact: Michel HASSELMANN, MD 33 3 88 11 50 41 michel.hasselmann@chru-strasbourg.fr | |
Service de Pneumologie - Hôpital de Hautepierre | Recruiting |
Strasbourg, France, 67098 | |
Contact: Romain KESSLER, MD 33 3 88 12 78 37 romain.kessler@chru-strasbourg.fr | |
Principal Investigator: Romain KESSLER, MD | |
Sub-Investigator: Vincent ROSNER, MD | |
Service de Pédiatrie II | Recruiting |
Strasbourg, France, 67098 | |
Contact: Laurence WEISS, MD 33 3 88 12 83 31 laurence.weiss@chru-strasbourg.fr | |
Principal Investigator: Laurence WEISS, MD |
Study Director: | Laurence KESSLER, MD | Hôpitaux Universitaires de Strasbourg |
Study ID Numbers: | 3887 |
Study First Received: | May 18, 2007 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00476281 |
Health Authority: | France: Ministry of Health |
Digestive System Diseases Genetic Diseases, Inborn Respiratory Tract Diseases Cystic Fibrosis Fibrosis |
Lung Diseases Diabetes Mellitus Infant, Newborn, Diseases Pancreatic Diseases Cystic fibrosis |
Pathologic Processes |